Literature DB >> 16115120

The measurement and application of thrombin generation.

Trevor Baglin1.   

Abstract

It is the capacity to generate thrombin, and the enzymatic work that thrombin does, that determines blood coagulability. Therefore, measurement of the enzymatic work potential of thrombin provides a method for quantifying the composite effect of the multiple factors that determine coagulation capacity. The application of measurement of thrombin generation to clinical decision making has been hampered by numerous technical difficulties and pitfalls, many of which have now been overcome. Technical advances now permit rapid, reproducible measurement. A review of clinical studies performed to date indicates the need to appreciate the precise methodology used in each case and the need to consider standardisation in future studies. Applying thrombin generation measurement to clinical decision making will require up-to-date estimates of risks relating to the disorder and the intended therapeutic intervention. Ultimately management studies will be required if the clinical utility of measurement of thrombin generation is to be proven.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115120     DOI: 10.1111/j.1365-2141.2005.05612.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  21 in total

1.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

2.  Mutation-prone points in thrombin receptor.

Authors:  Viroj Wiwanitkit
Journal:  J Thromb Thrombolysis       Date:  2007-12-07       Impact factor: 2.300

3.  Kinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies.

Authors:  Alexander Y Mitrophanov; Alisa S Wolberg; Jaques Reifman
Journal:  Mol Biosyst       Date:  2014-07-29

4.  Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.

Authors:  Roza Badr Eslam; Florian Posch; Irene M Lang; Thomas Gremmel; Beate Eichelberger; Cihan Ay; Simon Panzer
Journal:  J Cardiovasc Transl Res       Date:  2014-01-17       Impact factor: 4.132

5.  Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II.

Authors:  Suryakala Sarilla; Sally Y Habib; Dmitri V Kravtsov; Anton Matafonov; David Gailani; Ingrid M Verhamme
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

6.  Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.

Authors:  Fabrizio Semeraro; Concetta T Ammollo; Nicola Semeraro; Mario Colucci
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

7.  Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study.

Authors:  P L Lutsey; A R Folsom; S R Heckbert; M Cushman
Journal:  J Thromb Haemost       Date:  2009-07-28       Impact factor: 5.824

8.  Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin.

Authors:  Romy M W Kremers; Stéphane Zuily; Hilde Kelchtermans; Tessa C Peters; Saartje Bloemen; Véronique Regnault; H Coenraad Hemker; Philip G de Groot; Denis Wahl; Bas de Laat
Journal:  Blood Adv       Date:  2018-06-12

9.  Assessing thrombin generation at the point of care.

Authors:  T Keith Brock; Nicole L Gentile; Richard F Louie; Nam K Tran; Tyler Kitano; Gerald J Kost
Journal:  Clin Chem       Date:  2009-01-23       Impact factor: 8.327

10.  Preliminary hemocompatibility assessment of an innovative material for blood contacting surfaces.

Authors:  Martina Todesco; Elena Pontara; Chunyan Cheng; Gino Gerosa; Vittorio Pengo; Andrea Bagno
Journal:  J Mater Sci Mater Med       Date:  2021-07-27       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.